<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619034</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001697-84</org_study_id>
    <secondary_id>XAVOT</secondary_id>
    <nct_id>NCT00619034</nct_id>
  </id_info>
  <brief_title>Pharmacological Intervention in Diabetic Retinopathy</brief_title>
  <acronym>XAVOT</acronym>
  <official_title>Pharmacological Intervention Against Diabetic Retinal Flow Disturbances.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if diabetic retinopathy can be treated with
      prostaglandin analogues, prostaglandin synthesis inhibitors or carbonic anhydrases
      inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disturbances in retinal perfusion is believed to be involved in the pathophysiology of
      diabetic retinopathy. These disturbances may be due to changes in the basal diameter of
      retinal arterioles and to disturbances in the autoregulation of the diameter of these vessels
      when the blood pressure and the retinal metabolism changes. In vitro studies have shown that
      prostaglandins and carbonic anhydrases inhibitors are involved in the tone regulation of
      retinal arterioles, but it is unknown whether this finding is relevant in clinical practice.
      This can be tested in vivo by an retinal vessel analyzer measuring the dynamics of the
      retinal vessel diameter changes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter of retinal blood vessels</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence on retinal blood flow in diabetes</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical intervention cross-over</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>medical intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dorzolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dorzolamide eyedrops twice daily in one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost, diclofenac and dorzolamide (eyedrops)</intervention_name>
    <description>1 eyedrop twice daily in one week</description>
    <arm_group_label>latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
    <other_name>Voltaren ophtha</other_name>
    <other_name>Trusopt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>dicolfenac eyedrops twice daily i one eye</description>
    <arm_group_label>diclofenac</arm_group_label>
    <other_name>Voltaren ophtha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzolamide</intervention_name>
    <description>dorzolamide eyedrops twice daily, in one eye for one week</description>
    <arm_group_label>dorzolamide</arm_group_label>
    <other_name>Trusopt eyedrops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 1 with moderate diabetic retinopathy/healthy

          -  Blood pressure &lt; 135/85 mmHg

        Exclusion Criteria:

          -  Eye disease (excluding diabetic retinopathy)

          -  Allergic

          -  Kidney disease

          -  Liver disease

          -  Severe asthma

          -  Heart disease

          -  Hypertension arterial

          -  Users of drugs that influence the metabolism of the prostaglandins in the carbon
             dioxide

          -  Pregnant and breastfeeding women and women who don't use secure contraception

          -  Persons who can't do without contact lens in the treated eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrine K Tilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology - Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>December 28, 2010</last_update_submitted>
  <last_update_submitted_qc>December 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ã˜jenafd. J</name_title>
    <organization>Department of Ophthalmology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 7, 2011</submitted>
    <returned>August 2, 2011</returned>
    <submitted>August 15, 2011</submitted>
    <returned>September 19, 2011</returned>
    <submitted>September 29, 2011</submitted>
    <returned>November 2, 2011</returned>
    <submitted>January 20, 2012</submitted>
    <returned>February 21, 2012</returned>
    <submitted>August 3, 2012</submitted>
    <returned>August 31, 2012</returned>
    <submitted>October 25, 2012</submitted>
    <returned>November 23, 2012</returned>
    <submitted>January 11, 2013</submitted>
    <returned>February 12, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

